J&J seeks full Remicade rights as Schering-Plough/Merck & Co merger forges ahead
This article was originally published in Scrip
Executive Summary
Johnson & Johnson is to ask an arbitrator to dissolve its Remicade (infliximab) arthritis distribution agreement with Schering-Plough in the wake of the proposed merger of Schering-Plough and Merck & Co. If the agreement is terminated, J&J will regain full return of the rights to Remicade and the follow-on product golimumab (Simponi).